Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Healthy Subjects
Interventions: Quizartinib, Placebo; Drug · Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Meningococcal Disease
Interventions: MenABCWY, Placebo, MenACWY; Biological · Other
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more

Conditions: Epilepsy
Interventions: BIA 2-093, Moxifloxacin, Placebo; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Gastroparesis
Interventions: Buspirone, Placebo; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: COVID, Covid-19, Corona Virus Infection, Coronavirus Infection, Coronavirus-19, SARS-CoV2, SARS-CoV Infection
Interventions: Ivermectin, Doxycycline Hcl, Zinc, Vitamin D3, Vitamin C; Drug · Dietary Supplement
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Ventura, California

Conditions: Vascular Aging
Interventions: Placebo, Sodium Nitrite; Drug
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 50 Years to 79 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions: Lonapegsomatropin, Placebo, Somatropin; Drug · Other
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 23 Years to 80 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more

Conditions: Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
Interventions: QR-313, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 4 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 4
States / cities: Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more

Conditions: HIV Prevention
Interventions: Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation; Drug
Lead sponsor: Ian McGowan; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: Essential Tremor, Deep Brain Stimulation
Interventions: Alternating stimulation, Placebo; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Renal Anemia
Interventions: AND017, Placebo; Drug
Lead sponsor: Kind Pharmaceuticals LLC; Industry
Eligibility: 20 Years to 74 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more

Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Male only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • Newport Beach, California • Orange, California + 3 more

Conditions: Cognitive Impairments, Schizotypal Personality Disorder
Interventions: DAR-0100A, Placebo; Drug
Lead sponsor: Larry J. Siever; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Moderate and Severe Plaque Psoriasis
Interventions: Placebo, AEB071; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 10
States / cities: Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more

Conditions: Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions: Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Major Depressive Disorder
Interventions: R228060, Placebo and Paroxetine; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Interventions: ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more

Conditions: Arthritis, Gouty
Interventions: canakinumab, dexamethasone, placebo matching canakinumab, placebo matching dexamethasone; Biological · Drug · Other
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Birmingham, Alabama • New Brunswick, New Jersey

Conditions: Healthy Volunteers
Interventions: Rosuvastatin, Placebo; Drug
Lead sponsor: Sony Tuteja; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Phildelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Trazodone Hydrochloride (HCl) Extended-Release Tablets, Placebo; Drug
Lead sponsor: Labopharm Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 28
States / cities: Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 25 more

Conditions: Clostridium Difficile Infection
Interventions: SER-262, Placebo; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more

Conditions: Vaginal Odor
Interventions: Orally-administered probiotic, Placebo; Dietary Supplement
Lead sponsor: Bonafide Health; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Harrison, New York

Conditions: Methamphetamine Dependence
Interventions: Modafinil; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Lafayette, California • San Francisco, California

Conditions: Insomnia
Interventions: Trazodone, Eszopiclone, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 35
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 31 more

Search by objective public record fields.

A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Buspirone for Early Satiety and Symptoms of Gastroparesis

Trial of Combination Therapy to Treat COVID-19 Infection

Sodium Nitrite to Treat Arterial Aging

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Contributions to Hypertension With Androgen Deprivation Therapy

A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

Investigation of the Gut Microbiome and Statin Response

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

The Effects of an Orally-Administered Probiotic on Vaginal Symptoms

A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence

National Adaptive Trial for PTSD Related Insomnia